Cytokinetics, Incorporated (NASDAQ: CYTK) today announced that the first subject has been dosed in a Phase 1, randomized, double-blind, placebo-controlled ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Cytokinetics (CYTK) Tops Q4 EPS by 4c, Revenues Beat; Offers FY19 Revenue Mid-Point Guidance Above ConsensusFebruary 21, 2019 4:02 PM Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin ActivatorFebruary 20, 2019 9:02 AM